Drewa Julia, Lazar-Juszczak Katarzyna, Adamowicz Jan, Juszczak Kajetan
Department of Urology and Andrology, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, Poland.
Primary Health Care Clinic of the Ujastek Medical Center, Krakow University of Health Promotion, 31-158 Cracow, Poland.
Cancers (Basel). 2025 May 6;17(9):1576. doi: 10.3390/cancers17091576.
GLP-1 receptor agonists are valuable therapeutic agents for managing obesity and type 2 diabetes. The link between prostate cancer and obesity was described. The modulation of incretin hormone-dependent pathways may decrease the prostate cancer aggressiveness and progression.
The purpose of this study was to review and summarize the literature on the role of GLP-1 agonists in prostate cancer.
MATERIAL & METHODS: We performed a scoping literature review of PubMed from January 2002 to February 2025. Search terms included "glucagon-peptide like 1", "incretin hormone", "GLP-1 receptor agonist", and "prostate cancer". Secondary search involved reference lists of eligible articles. The key criterion was to identify studies that included GLP-1 receptor, incretin hormones, GLP-1 receptor agonists, and their role in prostate cancer development.
77 publications were selected for inclusion in this review. The studies contained in publications allowed us to summarize the data on the role of GLP-1 receptor and it's agonists in prostate cancer biology and development. The following review aims to discuss and provide information about the role of incretin hormones in prostate cancer pathogenesis and its clinical implication in patients with prostate cancer.
Incretin hormone-dependent pathways play an important role in prostate cancer pathogenesis. Moreover, GLP-1 receptor agonists seems to be a promising therapeutical agents when it comes to finding new therapies in patients with more aggressive and/or advanced stages of prostate cancer.
胰高血糖素样肽-1（GLP-1）受体激动剂是治疗肥胖症和2型糖尿病的重要药物。已有研究描述了前列腺癌与肥胖之间的联系。肠促胰岛素依赖性途径的调节可能会降低前列腺癌的侵袭性和进展。
本研究的目的是回顾和总结关于GLP-1激动剂在前列腺癌中作用的文献。
我们对2002年1月至2025年2月期间的PubMed进行了范围综述。检索词包括“胰高血糖素样肽-1”、“肠促胰岛素”、“GLP-1受体激动剂”和“前列腺癌”。二次检索涉及符合条件文章的参考文献列表。关键标准是确定包括GLP-1受体、肠促胰岛素、GLP-1受体激动剂及其在前列腺癌发生发展中作用的研究。
77篇出版物被选入本综述。这些出版物中的研究使我们能够总结关于GLP-1受体及其激动剂在前列腺癌生物学和发展中作用的数据。以下综述旨在讨论并提供有关肠促胰岛素在前列腺癌发病机制中的作用及其对前列腺癌患者临床意义的信息。
肠促胰岛素依赖性途径在前列腺癌发病机制中起重要作用。此外，在寻找针对侵袭性更强和/或晚期前列腺癌患者的新疗法时，GLP-1受体激动剂似乎是一种有前景的治疗药物。
